Introduction
Sample size estimation (SSE) consists in estimating the sample size required by a statistical test for achieving a predefined power. In the parametric framework the power is a function of the true effect size (ES), so that SSE can be accomplished through the estimation of this ES. In practice, the true ES is unknown (being this latter the object of the research) and it can be estimated on the basis of data from a pilot study. Subsequently, the sample size for the further study is estimated. For simplicity, and to establish SSE in the context of clinical trials, we assume that the pilot and the subsequent experiments are a phase II and a phase III trial, respectively. SSE is an intuitive practice that has been adopted by many authoritative authors (see for example Rosner, 2005, Ch.8; Efron and Tibshirani, 1993, Ch.25) .
In the last decade, the conservative approach to SSE (i.e. CSSE), which accounts for the variability of phase II data, has been proposed under both the frequentist (Shao and Chow, 2002, Sec.5 .2) and the Bayesian approach (Chuang-Stein, 2006 ).
The introduction, according to Wang et al.(2006) , of a launch threshold in the setting of CSSE (i.e. phase III is launched, and its sample size is estimated, only when phase II shows effect size over a predefined threshold of a certain clinical importance) represents a strong link between theory and practice: on one hand the launching threshold rationalizes a step often adopted in practice, and on the other Some papers report comparisons among different CSSE strategies. Wang et al. (2006) evaluated three frequentist CSSE strategies, mainly on the basis of launch probability and of the Average Power of phase III (i.e. the average of the random power given by the randomness of sample size estimators, provided that the phase III trial was launched). These performance indicators were computed under four different Scenarios: in Scenario 1 the effect size of phase II was equal to that of phase III; in Scenarios 2-4 phase III effect size was lower than that of phase II. The authors concluded by suggesting the adoption of the conservative strategy consisting in the use of the effect size observed in phase II minus one time its standard error, in order to then compute the sample size for phase III. Note that in Scenarios 2-4 the authors studied the robustness of the three strategies.
Let us now introduce the Overall Power (OP) of the phase II and the phase III, that is the probability to launch times the Average Power. Fay et al. (2007) compared, mainly on the basis of a modified for continuity version of the OP, the simple pointwise frequentist approach with two Bayesian techniques. Scenario 1 alone was considered and the authors suggested the adoption of a corrected Bayesian strategy. (In detail, to compute the OP Fay et al. (2007) set the launch threshold at −∞ and when the effect size was estimated to be under the null hypothesis they estimated the sample size for the phase III, for continuity, to be ∞; then, in these cases, and when the alternative hypothesis was true, i.e. when estimating the sample size has a practical sense, the phase III power was considered to be 1. Further details and comments can be found in De Martini, 2010.) It is worth noting that, from the perspective of statistical methodology classification, Hung et al.(2006) argued that SSE, and CSSE too, can be viewed as a kind of adaptation by design. strategies, as well as the mean and the MSE of sample size estimators, were computed. The launch threshold was adopted. Bayesian strategies performed poorly since they showed a very high mean and/or MSE of sample size estimators. COS clearly performed better than the other frequentist conservative strategies, both in terms of OP and of sample size estimators behavior (viz. MSE). Costs and experimental times are, therefore, considerably reduced and standardized. These results were computed solely under Scenario 1.
Broader and more heterogeneous patient populations are often pursued in phase III clinical trials as compared to in phase II studies. This might induce larger variability and/or lower average differences between drugs in primary endpoints variables. Both phenomena imply that standardized phase III effect sizes are lower than phase II ones. Wang et al.(2006) modeled these situations in Scenarios 2-4.
Our aim is now to study the robustness of some frequentist, Bayesian and optimized (viz. COS) CSSE strategies through the evaluation of their performances under these latter Scenarios. Then, some techniques for correcting the difference between phase III and phase II effect size, that are usually adopted under these Scenarios, are discussed and a new one is introduced. The robustness of CSSE strategies improved by this correction technique are, hence, examined.
The paper is as follows: Section 2 deals with the theoretical framework, and Section 3 with CSSE strategies which will be compared, under Scenarios 2-4, in Section 4. Section 5 is devoted to the techniques of bias correction and to the application of the new one to CSSE strategies. In Section 6, a comparison among the corrected versions of our CSSE strategies is presented; Section 7 contains the discussion, and Section 8 the conclusions.
Theoretical framework
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Being m 1 = m 2 = m the sizes of the samples drawn from each group in phase III, the test statistic is T m = m/2(X m −Ȳ m ). Given the type I error α, the true power of the phase III trial is π δ3 (m) = P δ3 (T m > z 1−α ) = Φ(δ 3 m/2 − z 1−α ), where
, and Φ is the distribution function of the standard normal.
The ideal sample size per group for phase III is, therefore,
where 1 − β is the power to be achieved. In practice we are required to estimate M I , since δ 3 is unknown.
The effect size of phase II is δ 2 = µ 2,T − µ 2,C . Being n 1 = n 2 = n the sample size for each group in phase II, let d
• 2,n be a generic estimator of δ 3 based on phase II data, where "•" represents a generic CSSE strategy. We apply the launching criterion introduced by Wang et al.(2006) 
Hence, the OP (i.e. the probability of rejecting during phase III, when M I is estimated on the basis of phase II data) is:
The average of sample size estimators is then
Remark 1. Although we used δ 2 and δ 3 for defining the effect sizes of phase II and phase III, it should be noted that the effect the drug has is not a function of the development phase of the sponsor. Instead, there are different treatment effects for the population studied for particular phase II and phase III protocols. Nevertheless, when δ 2 = δ 3 a structural bias arises within SSE. In this Section five different CSSE strategies are recalled and are to be compared in Section 4 in order to evaluate their robustness. For each strategy, motivation for inclusion in our study is explained.
Pointwise strategy (PWS). It is the fixed-γ conservative strategy with γ = 50%: in practice, the observed effect size d 2,n is adopted and the sample size estimator is
This strategy is considered because it is the simplest, and also because the results regarding the estimation of the sample size under Scenario 1 were quite good (De Martini, 2010) .
One standard error conservative strategy (1SES). In this strategy, 1 standard error is subtracted from d 2,n to obtain a conservative estimate of δ 3 . This corresponds to 84.1% conservative strategy, so that d it is included in this comparison because Wang et al.(2006) , who also considered Scenarios 2-4, deem it should be adopted.
Third quartile conservative strategy (3QS). To adopt 75% conservative strategy appears a reasonable choice, because in this way the probability of planning an underpowered experiment is reduced to the fixed rate of 1/4. Hence, d
• 2,n = d 75% 2,n and the sample size estimator is M 75% n . We consider this fixed-γ strategy too because the performances of 3QS in terms of OP under Scenario 1 were closer to COS than those of PWS and 1SES.
Calibrated optimal strategy (COS). This strategy is based on the fact that if a fixed-γ conservative strategy is adopted, then its OP (say OP n (γ)) turns out to be a concave function of γ. Consequently, we introduced an optimization for OP n (γ) (De Martini, 2010) , with the constraint of not exceeding 1 − β. Being that optimum (say γ O,n ) unknown, it can be estimated through the plug-in principle and its estimate is g O,n . With COS d
• 2,n = d 2,n and the sample size estimator is Bayesian truncated strategy (BAT). In a Bayesian framework, the posterior distribution of δ 2 given d 2,n is, with noninformative prior, N (d 2,n , 2/n), and it is used for making inference on δ 3 . Consequently the Bayesian estimate of the true power Remark 2. With γ conservative strategies the OP in (1) simplifies to
Without loss of generality, we assume δ 2 = δ 3 /k so that (2) becomes:
Remark 3. It should be noted that Fay et al.(2007) considered the variance to be unknown and that they used the fiducial distribution of the effect size, actually not a Bayesian posterior. Nevertheless, it is easy to show that in case the variance is known the fiducial distribution reduces to the Bayesian posterior with noninformative prior, i.e. N (d 2,n , 2/n).
Evaluating the robustness of CSSE strategies
Here the performances of the five strategies presented in the previous Section are considered under Scenarios 2-4 of Wang et al.(2006) . In Scenario 2 the phase III effect size is quite a bit (20%) lower than in phase II, and the launch threshold is set equal to the phase III effect size. In Scenario 3 the ratio between phase II and phase III effects size is the same as in the latter case, and the launch threshold is set at a value somewhat lower than δ 3 . In Scenario 4 the phase III effect size is much lower (50%) than in phase II, and the launch threshold is set as in Scenario 3.
In order to evaluate the performances of the strategies their OP, which is an important evaluation tool, is computed. Then, focusing on the behavior of sample size estimators, their bias (i.e.
and their variability must be evaluated. The MSE of sample size estimators is in particular taken into consideration -this concerns both bias and variability, since it is the sum of the square of the bias with the variance. We also report the mean of sample size estimators.
Design of the study
In a recent work we stated (De Martini, 2010 ) that phase II sample sizes n between M I /3 and 4M I /3 were the most important from a practical point of view, and that higher values of n were evaluated to look at the asymptotic behavior of SSE strategies only. Now, it should be noted that under Scenarios 2-4 sample size estimation is not
Then, the behavior of SSE strategies is not relevant for high values of n either from a practical standpoint or from a theoretical one. As regards the level of the power to be achieved, argued that 1−β = 80% is a low power for CSSE, and this point is confirmed in De Martini (2010). Here, under Scenarios 2-4 where
choice of 80% appears even more penalizing.
Consequently, for evaluating robustness only three n settings are considered in all Scenarios (i.e. 2M I /3, M I and 4M I /3, avoiding n = M I /3 because of the poor performances of all strategies under Scenario 1), and the power is set at 1 − β = 90%.
As regards the effect size parameters, in Scenario 2 we set δ 3 = 0.2, 0.5, 0.8, k = 0.8
(that implies δ 2 = δ 3 /0.8) and δ 0L = δ 3 ; we, therefore, consider 9 settings (i.e. 3 ns × 3 δs). In Scenario 3 we set the launch threshold δ 0L at 0.1, with δ 3 = 0.2, 0.5, 0.8; then we set δ 0L = 0.25, with δ 3 = 0.5, 0.8; as in Scenario 2, we have δ 2 = δ 3 /0.8; we, therefore, consider 15 settings (i.e. 9 + 6). In Scenario 4 we set δ 3 = 0.2, 0.5, 0.8, k = 0.5 (i.e.
δ 2 = δ 3 /0.5) and δ 0L = 0.1, so that 9 settings are considered. 
Results
Under Scenarios 2 and 4 all strategies do not present robust behavior. Being Scenario 3 the closest to Scenario 1, the strategies show better performances. In scenario 2 the best performer is BAT, which shows the maximum OP (62.7%) with δ 3 = 0.8 and n = 4M I /3; its minimum was 55.9%, with δ 3 = 0.2 and n = 2M I /3.
The OPs are so low that a discussion on the MSE and the average of sample size estimators is unnecessary. These poor performances are due to too high launch threshold settings with respect to true effect sizes, inducing low launch probabilities, with subsequent low OPs.
In Scenario 4 the best performer is 1SES, whose OP is around 50% with every δ 3
and n. A fortiori we do not discuss MSEs. Poor performances under this Scenario are caused by too large differences between the effect sizes of the two phases, i.e. Nevertheless, the OPs are a bit lower than those of Scenario 1, as are the MSEs, as a consequence of the differences between phase III and phase II ES.
As it concerns strategy comparison, the (expected) better performances of COS are not as clear as under Scenario 1. It can be easily noted that COS performs better than PWS (higher OP, lower MSE, average sample size closer to M I ). As regards BAT, although the average over all 15 settings of its OPs is 3.3% larger than that of COS (which seems in any case acceptable resulting 77.5%), we still prefer COS because its average sample size is closer to M I and it mainly presents a dramatically lower MSE: the absolute error (i.e. MSE 1/2 ) of BAT is more than 4 times higher than that of COS, on average over all 15 settings (i.e. the average of the rates of MSE 1/2 of BAT with respect to those of COS among the 15 settings is 4.16, in other words 316% higher). Among 3QS and 1SES, which perform similarly, we prefer the former: although the OP of 1SES is 2.0% larger, its MSE 1/2 is higher too (40%) with 
Bias correction
In the previous Section we evaluated the robustness of CSSE strategies when a structural bias is present, resulting from differences between phase II and phase III effect sizes (see also Remark 1). This bias, as well as those present in other branches of statistical theory, can nonetheless be corrected or at least reduced. In this Section an intuitive technique of bias correction is presented, and the corrected CSSE strategies related to those recalled in Section 3 are derived.
In the context of CSSE the authors usually suggest to modify the type I and/or type II errors to reduce the bias. Fay et al. (2007) , although no structural bias was considered (i.e. δ 2 = δ 3 ), observed that the Bayesian CSSE strategy provided an OP higher than requested, and so applied a correction to the nominal power (e.g. a power of 76% was suggested for 1 − β = 80%). Wang et al.(2006) , in presence of a structural bias, suggested techniques based on the modification of the type I and/or type II errors. One of these techniques consists in applying β * < β. It is worth noting that the launch probability is not modified, whereas the correction influences sample size estimators merely. Wang et al.(2006) argue that these strategies are quite suitable under Scenarios 2-4, when applied to 1SES. For example when δ 2 = 0.3 and δ 3 = 0.2, if α = 0.025 and 1 − β = 80%, then 1 − β * = 92% is suggested. Note that their conclusions are based on the computation of the average of sample size estimators only (see Table 4 in their work). 
Postulating the correction for the effect size
Our proposal concerns a correction to be applied directly on the effect size. In practice, the corection should be applied to the effect size estimator d
• 2,n . This idea stems from two observations: on one hand, CSSE aims at studying the performances
,n , which is, under Scenarios 2-4, a biased (and non consistent) estimator of δ 3 ; on the other hand, the structural bias can be modeled through δ 2 = δ 3 /k. Hence, to improve CSSE performances we find it natural and intuitive to speculate first about k. Being k c the postulated correction, M
• n can be directly modified by using d
,n only, in its formula. We then obtain c M • 2,n . Consequently, the assumption on M max changes, and the new maximum is
Finally, note that the launch probability is not modified by the correction suggested here, and this is in accordance with those proposed by Wang et al.(2006) .
Indeed, d
• 2,n remains the same, M
• n alone is modified.
Corrected CSSE strategies
Corrected fixed-γ strategies (viz. PWS, 1SES, 3QS). The γ conservative estimator of δ 3 is multiplied by the correction k c , obtaining c d γ 2,n = (d 2,n − z γ / n/2) * k c , and,
Corrected COS. We first refer to the corrected version of the estimated OP, which, following from (3), is:
Then, being g O,n the argument of the constrained maximum of (4), we make use of 2 + 1 in order to make it closer to M I . Corrections can be brought to the numerator or to the denominator (as we suggest). For each correction on the numerator there exists an equivalent correction for the denominator: for example, for every β * < β there exists k c < 1 such that 
A study comparing corrected CSSE strategies
We here evaluate the performances of the five corrected strategies introduced in Section 5.
Design of the study
Scenario 3 alone of the previous Section 4 is examined, with the 9 settings where δ 0L = 0.1. We recall that k = 0.8. As regards k c , there are three postulated corrections: a smaller than necessary one, i.e. k c = 0.9, the right one, i.e. k c = 0.8, and a higher than necessary one, i.e. k c = 0.7. So, 27 settings are evaluated (3 ns × 3 δ 3 s × 3 k c s). Since our CSSE strategies are consistent when k c = 0.8, we also evaluate their asymptotic behavior, with n up to 4M I , for the three δ 3 s. Once again, we look at OPs of CSSE strategies, and at the MSEs and averages of their sample size estimators. Table 2 reports OP, MSE and average of sample size estimators obtained with δ 3 = 0.5 alone, i.e. under 9 settings out of 27. When δ 3 < δ 2 , applying a correction k c < 1 improves the OPs of all strategies, but also increases their MSEs. The averages of sample size estimators increase too, and the bias augments in all circumstances but one (i.e. for PWS with k c = 0.9).
With k c = 0.9, the OPs improve, on average over the 9 settings, from 4% (1SES) to 6.8% (PWS), but they are still lower than 90% (from 80.1% of PWS to 88.5% of 1SES In practice, the corrected COS provides the second best improvement in OP and the second smallest increase in MSE 1/2 (19%). Moreover, the MSE 1/2 of COS is still the lowest: those of PWS, 3QS, 1SES and BAT are, on average, 1.28, 2.53, 3.53 and 5.04 times higher, respectively. Since COS was the best performer under Scenario 3, it remains the recommended strategy even with a smaller than necessary correction. With a higher than necessary correction, i.e. k c = 0.7, the OPs of all strategies result higher than 90%, going, on average, from 92.3% (PWS) to 95.1% (BAT) (COS, 94.0%). Nevertheless, the MSE 1/2 increases, on average, from 2.14 times with PWS to 2.46 times with COS, with respect to those obtained without correction. Also, the averages of sample size estimators are much higher than M I . These performances are caused by too high sample size estimates provided by this excessive correction.
In the light of sample size estimator behaviors, it would be preferable to avoid higher than necessary corrections. As regards detailed results, the MSE 1/2 of COS is once again the lowest: the enlargements of the other strategies go from 12% of PWS to
With the right correction of k c = 0.8, all strategies converge, as n tends to ∞:
their OPs tend to 90% and the MSEs tend to zero. (see Figures 1 and 2 ). It should also be noted that when 2M I ≤ n ≤ 4M I /3, all strategies provide OPs closer to 90% than those obtained with k c = 0.9. Furthermore, considering these pilot sample sizes 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 F o r P e e r R e v i e w O n l y of practical interest, COS converges faster. Indeed, the strategy with averaged OP (over the usual 9 settings) closest to 90% is COS (89.4%), where the highest differences are provided by 1SES (91.8%). The MSE 1/2 increases, as expected, from 51% of PWS to 74% of 1SES, with respect to that provided by the strategies without correction.
Also, the MSE of COS is the lowest: the enlargements in MSE 1/2 go from 21% of PWS to 4.75 times (i.e. 375%) of BAT. Once again COS is recommended, and this was expected, since postulating the right correction makes estimations quite close to those under Scenario 1.
Finally, we emphasize that the OPs provided by all corrected strategies are a little higher (and closer to 90%) than the respective ones computed in De Martini (2010) under Scenario 1, i.e. where correction was not needed (see Figure 1) . Moreover the MSEs with k c = 0.8 are comparable to those under Scenario 1 (see Figure 2 ). These behaviors are due to higher launch probabilities with respect to Scenario 1 (due to δ 2 > δ 3 ), and to quite close sample size estimation.
Discussion
The statistical literature contains many works on SSE for planning a generical experiment, as well as, in particular, a randomized controlled trial. Over the last five years, the conservative approach to SSE, which takes into account the variability of phase II pilot data, has been proposed under some different approaches. Chuang- the so-called Scenario 1). COS resulted the best strategy, with good OPs, and with MSEs considerably lower than those of the other strategies. Nevertheless, the size of the phase II sample used for CSSE should be around the ideal phase III sample size, the launch threshold should be lower than one half of the true phase III effect size, and the prefixed power should be set at 90%. These three assumptions were considered as operating CSSE conditions.
In practice, small deviations from Scenario 1 would not substantially change these results. Nevertheless, in some circumstances the difference between phase II and phase III effect sizes can be not negligible, for example in the presence of a more restrictive inclusion criteria in phase II, or even when a lack of knowledge of dose-response relationship occurs. In these cases, phase III effect size is often lower than phase II. Consequently, not only CSSE becomes inconsistent for large samples, but it might also provide bad results for finite phase II sample sizes of practical interest. Wang et al.(2006) considered some of these situations (viz. Scenarios 2-4),
where CSSE was applied in the presence of bias.
In this work, we have compared the performances of some Bayesian and some frequentist CSSE strategies with COS under Scenarios 2-4, in order to evaluate whether COS would still have provided good results. The results were mainly based on OP and MSE. As regards Scenarios 2 and 4, COS, unlike under Scenario 1, did not improve the performances of fixed-γ or of Bayesian estimators, and we confirmed the results in Wang et al. (2006) , where all strategies performed poorly. In Scenario 2 there was the problem of a too high launch threshold, so we confirm that it would be better to set δ 0L < δ 3 /2. In Scenario 4 poor performances were due to the high difference between the effect sizes of phase II and phase III. COS was still the best performer (thanks to its low MSE) under Scenario 3, although its supremacy is not as clear as in Scenario 1. Assuming the continuity of the performances of different strategies when the ratio k between δ 2 and δ 3 changes, in the light of results under Scenarios 1 and 3 we find that for small differences between δ 2 and δ 3 (i.e. δ 3 /δ 2 ≥ 0.8)
COS remains the best strategy. In practice, COS is a very good strategy when CSSE is consistent, that is under Scenario 1 when δ 2 = δ 3 : in this case COS converges quickly, and with small variability. Consequently COS suffers when a structural bias is present (i.e. δ 2 = δ 3 ), and Now, it should be noted that there exist some techniques for correcting bias in CSSE. Wang et al. (2006) suggested correcting α or/and β levels, in accordance with some other works in the field. Here, we proposed to apply the correction directly on the source of the bias, that is on the estimation of δ 3 . Indeed, in our opinion, to correct α and/or β is more complicated and counter-intuitive than directly correcting
,n , i.e the estimator of δ 3 . In particular, when the error levels are modified a check of the amplitude of the correction is missing. On the contrary, d
• 2,n can simply be modified by expressing the postulated correction k c . Hence, if k c is right, then CSSE is consistent and the structural bias is, asymptotically, corrected; otherwise, if k c is at least close to k, then this bias can be reduced, specifically for finite pilot sample sizes of practical interest. In both situations, the framework of CSSE returns to being close to Scenario 1, so that the peculiarity of COS can be exploited.
We, then, evaluated the behavior of k c -corrected CSSE under Scenario 3, i.e. when the phase III effect size is 20% lower than phase II. When the postulated correction is the right one, COS clearly performs better than the other strategies, providing good OPs and the smallest MSEs. It is worth noting that in this case the OPs of COS are even higher than those observed under Scenario 1 in De Martini (2010):
this is due to a higher launch probability, since δ 2 > δ 3 , and to a similar estimation performance. Hence, paradoxically, the bias can be exploited for improving CSSE, should the right correction be applied. When the postulated correction is smaller than necessary COS is still the best performer, and it works quite well in general.
A higher than necessary correction should be avoided.
Conclusions
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